NCT05268952View on ClinicalTrials.gov

A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment (Liquid-NET 2.0)

NARecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 27, 2019

Primary Completion Date

May 27, 2025

Study Completion Date

December 31, 2025

Conditions
Neuroendocrine Tumors
Interventions
OTHER

Liquid biopsies

Blood/urine sampling and scans are done at regular intervals

OTHER

Scans (CT, gallium-68 DOTATE/TOC/NOC PET-CT)

Scans will be done at regular intervals

Trial Locations (3)

2006

TERMINATED

Bank of Cyprus Oncology Center, Nicosia

2650

RECRUITING

Antwerp University Hospital, Edegem

9100

RECRUITING

VITAZ, Sint-Niklaas

All Listed Sponsors
collaborator

Universiteit Antwerpen

OTHER

lead

University Hospital, Antwerp

OTHER